Bill Novotny

Bill Novotny, M.D., is the Senior Vice President of Clinical Development at Prelude Therapeutics. He is a physician-scientist with a 30-year career spanning academic and basic science, hematology-oncology drug development, oncology diagnostics, and clinical practice of medicine. Bill led the development of Avastin, the first angiogenesis inhibitor for the treatment of colon, lung, and breast cancer, from Phase 1 to FDA approval. Other first-in-class drugs that Bill helped develop and bring to market include Herceptin for the treatment of breast cancer and enzalutamide for the treatment of prostate cancer. Prior to joining Prelude, Dr. Novotny was Senior Vice President of Hematology at BeiGene, where he oversaw the development, and approval of zanubrutinib in B cell malignancies and tislelizumab in Hodgkin lymphoma. He has held senior positions at GRAIL, Medivation, and Genomic Health. He began his career in biotech at Genentech, where he was Principal Medical Director from 1995 to 2009, leading the development of Avastin and Herceptin. Dr. Novotny is board certified in Hematology and Internal Medicine.